AEEA-AEEA Pharmaceutical Intermediates Professional Manufacturer |CongenPharma
Publish Time:
2025-08-19
Since the 1990s, polyethylene glycolation (PEGylation) has become a highly mature half-life extension technology in clinical practice, and its excellent safety has been verified by more than 30 years of clinical application. Currently, PEGylated drugs have been approved by drug regulatory authorities in most countries and regions around the world, and are widely used in intravenous injection, oral administration, and skin administration. They can modify various substances such as proteins, polypeptides, oligonucleotides, antibody fragments, organic small molecules, and nanoparticles.
In popular long-acting peptide drugs, semaglutide (Ozempic) and tirzepatide are both optimized by PEG modification by connecting fatty diacid side chains to the lysine position of the peptide chain. PEG modification not only makes the originally insoluble protein soluble and highly fluid, but also improves drug performance through multiple mechanisms: reducing kidney filtration, reducing pyrogenicity, reducing protease digestion, and protecting drug molecules from attack by the human immune system, thereby improving drug delivery efficiency. Because it can avoid the human body's defense mechanisms, the residence time of this type of drug at the site of action is significantly prolonged, effectively avoiding rapid kidney clearance and metabolic degradation, and greatly extending the half-life in the body.
AEEA-AEEA as the core raw material of the side chain structure of semaglutide (Ozempic) and tirzepatide (CAS No.: 1143516-05-5) The purity of the current AEEA-AEEA (CAS No.: 1143516-05-5) directly affects the quality of the two star drugs. However, the current synthesis of AEEA-AEEA) faces technical problems such as complex operation, high cost, low yield, and insufficient purity, which has become a key bottleneck restricting the production optimization of related long-acting drugs.
AEEA-AEEA structural formula
AEEA-AEEA pharmaceutical intermediate professional manufacturer | CongenPharma
As a professional manufacturer of pharmaceutical intermediate AEEA-AEEA,CongenPharma has redesigned the process route of AEEA, and adopted the amino-carboxyl synergistic protection-regeneration route, using diethanolamine and acyl chloride as raw materials, and obtained AEEA and diAEEA through three steps of amidation, condensation, and hydrolysis. (CAS No.: 1143516-05-5) mixture, and then AEEA and diAEEA pure products are obtained through sieving and crystallization respectively, and a related patent is submitted, application number: 202510057484.1.
The process reduces the use of protecting and deprotecting reagents, has high atom economy, and the raw materials are easy to obtain. The production cost of AEEA is 50% of the current commonly used process, and AEEA-AEEA (CAS No.: 1143516-05-5) The production cost is 30% of the existing production process, which has significant AEEA-AEEA price advantages. Based on the process, Tongjun Pharmaceutical Intermediate AEEA-AEEA (CAS No.: 1143516-05-5) has fewer related impurities, and the product quality far exceeds that of currently marketed products, with a purity of ≥99%, AEEA, 3AEEA≤0.1% (mole percentage).
